His main research interests are immunopharmacology and anti-tumor pharmacology, and he has presided over more than 30 national major new drug creation projects, national 1035 projects, national natural science foundation, Guangdong innovation team projects, Guangdong key research projects, and Guangzhou Guangdong key breakthrough projects. He has published more than 50 SCIentific research papers 150 and more than 30 sci papers in domestic and foreign journals, and won 5 second prizes for scientific and technological progress at the provincial and ministerial levels. He presided over 5 new drug research and development projects, 4 of which obtained new drug certificates and production approvals. In 2003, Lolatrak hydrochloride, a national first-class anti-tumor drug, was approved for listing by the State Food and Drug Administration. At present, the anti-tumor effect of IPL-032, a new multi-target tyrosine kinase inhibitor, is being studied, and it has been funded by the national major new drug creation plan project.